보고서 요약(국문)

시장 개요
전 세계 암 치료 유전체학 시장은 2022년 134억 달러 규모에 달했으며, 2030년까지 511억 달러 규모로 성장할 것으로 예상됩니다. 전 세계 암 치료 유전체학 시장은 2023년부터 2030년까지 연평균 18.9%의 성장률을 보일 것으로 전망됩니다.
유전체 분석은 암세포 내 특정 분자 표적을 식별하는 데 도움을 줍니다. 표적 치료는 이러한 표적의 활성화를 특이적으로 억제하거나 차단함으로써 정상 세포는 손상시키지 않고 암세포만 파괴할 수 있습니다. 예를 들어, HER2 양성 유방암에서 HER2 단백질을 표적으로 하는 트라스투주맙과 만성 골수성 백혈병에서 BCR-ABL 융합 단백질을 표적으로 하는 이마티닙과 같은 약물이 있습니다.
진단, 맞춤형 의학, 신약 개발 분야에서의 활용 증가가 암 치료 유전체학 시장 성장을 견인하고 있습니다. 암 발병률 증가, 조기 질병 진단에 대한 인식 제고, 고령 인구 증가, 기술 발전 등의 요인이 시장 성장을 견인하고 있습니다.
시장 동향
게놈 시퀀싱 기술의 발전은 예측 기간 동안 전 세계 암 치료 분야 유전체학 시장 성장을 촉진할 것입니다.
DNA 시퀀싱 및 뉴클레오티드 수준의 종양 유전체 분석을 통해 질병의 새로운 분자적 원인이 발견되었으며, 이는 암 생물학에 대한 이해를 혁신적으로 변화시키고 보다 효과적인 치료법과 환자 예후 개선의 길을 열었습니다.
단축 판독, 고처리량, 장축 단일 분자 및 나노포어 시퀀싱 방법을 포함한 광범위한 시퀀싱 플랫폼은 대량 조직에서 단일 세포에 이르기까지 다양한 분석에 활용될 뿐만 아니라, DNA 및 RNA 프로파일링 응용 분야에서 관심 유전자를 표적으로 하는 극저투입 라이브러리 준비 방법 및 증폭이 필요 없는 Cas9 기반 농축 전략과 같은 새로운 분자 접근법도 시장을 주도하는 기술입니다.

액체 생검의 도입이 예측 기간 동안 전 세계 암 치료 분야 유전체학 시장 성장을 촉진하고 있습니다.
암을 진단하고 치료하는 가장 효과적인 방법은 생검을 통해 종양 조직을 채취하는 것입니다. 미국 국립암연구소(NCI)에 따르면, 최첨단 약물이 증가하고 있음에도 불구하고 폐암은 세계에서 가장 치명적인 악성 종양 중 하나이며 매년 15만 명 이상의 목숨을 앗아갈 것으로 예상됩니다.
지난 10년간 액체 생검 플랫폼 개발의 혁신으로 혈액 기반 검사에 대한 규제 승인이 증가하면서 진행성 암 환자를 위한 정밀 암 치료가 변화하고 있습니다.
맞춤형 의학의 확장이 전 세계 암 치료 분야 유전체학 시장 성장 기회를 제공합니다.
미국 식품의약국(FDA)에 따르면, 맞춤형 의학과 표적 치료는 신약 개발에 있어 상당한 진전을 의미하며, 종양학은 특정 유형의 종양에 대해 가장 빠르게 성장하는 치료 분야 중 하나입니다. 표적 치료와 면역 치료는 맞춤형 의학에서 암 치료에 자주 사용되는 두 가지 유형의 약물입니다.
COVID-19 영향 분석
COVID-19 팬데믹은 암 치료 분야 유전체학 시장에 상당한 영향을 미쳤습니다. COVID-19 연구와 백신 개발에 연구 기관과 자금 지원처의 관심이 집중되었습니다. 이로 인해 암 치료 유전학 연구와 같이 COVID-19와 관련 없는 연구 사업에 대한 자금 지원이 지연되거나 제한되었을 수 있습니다. 이는 새로운 치료법이나 진단 도구 개발 및 진행 중인 유전체 연구의 진전에 영향을 미칠 수 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 암 치료 분야 유전체학 시장에 미치는 영향은 복잡하고 다면적입니다. 특히 암 치료 유전학 관련 의료 및 연구 프로젝트에 대한 자원과 자금 지원이 분쟁으로 인해 다른 곳으로 전용되었습니다.
의료 인프라 및 연구에 대한 투자가 정부의 우선순위에서 밀려나 분쟁의 즉각적인 영향 관리로 전환되면서 유전체 기술의 개발 및 보급에 영향을 미칠 수 있습니다.

세그먼트 분석
글로벌 암 치료 유전체학 시장은 제품, 기술, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.
유전체 시퀀싱 부문은 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
유전체 시퀀싱 부문은 2022년 암 치료 유전체학 시장에서 약 36.4%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 유전체 시퀀싱은 다양한 기술과 기법을 사용하여 수행할 수 있으며, 기술 발전으로 인해 유전체 시퀀싱을 더욱 빠르고 정확하며 경제적으로 수행할 수 있게 되었습니다.
차세대 시퀀싱(NGS) 기술은 유전체 시퀀싱에 혁신을 가져왔습니다. Sanger 시퀀싱과 비교하여 NGS 플랫폼은 방대한 양의 시퀀싱 데이터를 병렬로 생성할 수 있어 고처리량 시퀀싱을 가능하게 합니다. Illumina 시퀀싱과 같은 NGS 기술은 합성 시퀀싱 또는 연결 시퀀싱과 같은 다양한 전략을 사용하여 DNA 서열을 확인합니다.

지리적 분석
주요 업체 간 협력 및 파트너십 증가, FDA 승인 증가, 암 치료 분야 유전체학 발전이 북미 지역을 주도하고 있습니다.
북미는 암 치료 분야 유전체학 시장에서 약 39.9%의 점유율을 차지하며 시장을 선도할 것으로 예상됩니다. 시장 참여 업체들은 제품 출시 및 협력과 같은 전략을 통해 사업을 확장하고 있습니다. 예를 들어, 2023년 1월 아리마 지노믹스(Arima Genomics, Inc.)는 프로테안 바이오다이애그노스틱스(Protean BioDiagnostics)와 파트너십을 체결하여 아리마의 차세대 염기서열 분석(NGS) 기반 검사를 미국 내 의사들이 환자 관리에 활용할 수 있도록 제공한다고 발표했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Roche Diagnostics, AstraZeneca PLC, Illumina, Inc., Affymetrix, Agilent Technologies, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, Sigma Aldrich Corporation (Merck KGaA) 등이 있습니다.
보고서 구매 이유

• 제품, 기술, 응용 분야, 최종 사용자 및 지역별 글로벌 암 치료 유전체학 시장 세분화를 시각화하고 주요 사업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 암 치료 시장 수준의 유전체학 관련 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

글로벌 암 치료 유전체학 시장 보고서는 약 69개의 표, 69개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Genomics In Cancer Care Market reached US$ 13.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 51.1 billion by 2030. The Global Genomics In Cancer Care Market is expected to exhibit a CAGR of 18.9% during the forecast period 2023-2030.
The identification of specific molecular targets in cancer cells is aided by genomic analysis. Targeted therapies can destroy cancer cells while sparing healthy cells by specifically inhibiting or preventing the activation of these targets. For instance, drugs like trastuzumab, which targets the HER2 protein in HER2-positive breast cancer, and imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia.
The increasing application in diagnostics, personalized medicine, and drug discovery & development drives the genomics in cancer care market growth. Factors such as rising cancer incidence, increasing awareness about early disease diagnosis, growing geriatric population, and technological advancement drive market growth.
Market Dynamics
The Advancement in Genome Sequencing is Boosting the Global Genomics in Cancer Care Market Growth During the Forecast Period
In DNA sequencing and genomic analysis of tumors at the nucleotide level, new molecular causes of the disease have been discovered, revolutionizing our understanding of cancer biology and paving the way for more effective treatments and better patient outcomes.
A wide range of sequencing platforms, covering the present and future state of the art for short-read, high-throughput, and long-read single molecule and nanopore sequencing methods from bulk tissue to single cells, as well as novel molecular approaches for extremely low-input library preparation methods, targeting genes of interest in both DNA and RNA profiling applications, as well as amplification-free Cas9-based enrichment strategies, are among the technologies.
The Adoption of Liquid Biopsies is Boosting the Global Genomics in Cancer Care Market Growth During the Forecast Period
The most effective approach for identifying and treating cancer is the collection of tumor tissue through biopsies. According to the National Cancer Institute, with an increasing number of cutting-edge medications, lung cancer is one of the deadliest malignancies in the world and will likely claim the lives of over 150,000 people annually.
Precision cancer care for patients with advanced disease is changing due to innovations in the development of liquid biopsy platforms during the past ten years, which have resulted in an increasing number of regulatory approvals for blood-based testing.
The Expansion of Personalized Medicine Provides Global Genomics in Cancer Care Market Growth Opportunities
According to the FDA, personalized medicine and targeted therapies represent a substantial advancement in drug development, and oncology is one of the therapeutic fields that is growing the fastest for some types of tumors. Targeted therapies and immunotherapies are the two types of medicines that personalized medicine frequently uses in the treatment of cancer.
COVID-19 Impact Analysis
The COVID-19 pandemic has significantly impacted Genomics In The Cancer Care Market. The research on COVID-19 and the creation of a vaccine received significant attention from research institutions and funding sources. This may have caused delays or funding restrictions for research initiatives unrelated to COVID, such as genetics in cancer treatment. This might affect the development of novel treatments or diagnostic tools and the advancement of ongoing genomic studies.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on genomics in the cancer care market is complex and multifaceted. Resources and financing for healthcare and research projects, especially those involving genetics in cancer treatment, were diverted due to the conflict.
Investments in healthcare infrastructure and research reduced government priorities and moved towards managing the immediate effects of the conflict, which could have an impact on the development and uptake of genomics technology.
Segment Analysis
The Global Genomics In Cancer Care Market is segmented based on product, technology, application, End User and region.
The Genome Sequencing Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The genome sequencing segment accounted for the highest market stake, accounting for approximately 36.4% of the genomics in the cancer care market in 2022. Genome sequencing can be done using various techniques and technologies, and technological improvements have made it possible to sequence genomes more quickly, accurately, and affordably.
Next-generation sequencing (NGS) technologies have transformed genome sequencing. Compared to Sanger sequencing, NGS platforms can produce enormous amounts of sequencing data in parallel, enabling high-throughput sequencing. Different strategies, such as sequencing by synthesis or ligation, are used by NGS techniques, such as Illumina sequencing, to ascertain the DNA sequence.
Geographical Analysis
Increasing Collaborations and Partnerships Among the Key Players, Increasing FDA Approvals, and Advancement in Genomics in Cancer Care Dominate the North American Region
North America is expected to dominate the genomics in the cancer care market, accounting for around 39.9%. The market players are applying market strategies such as product launches and collaboration to expand their business. For instance, in January 2023, Arima Genomics, Inc. announced a partnership with Protean BioDiagnostics, to make a next-generation sequencing (NGS)-based test from Arima available to doctors for patient management in the United States.
Competitive Landscape
The major global players in the market include Roche Diagnostics, AstraZeneca PLC, Illumina, Inc., Affymetrix, Agilent Technologies, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, and Sigma Aldrich Corporation (Merck KGaA) (Merck KGaA) among others.
Why Purchase the Report?
• To visualize the Global Genomics In Cancer Care Market segmentation based on the product, technology, application, End User, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of genomics at the cancer care market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Genomics In Cancer Care Market Report Would Provide Approximately 69 Tables, 69 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The growing burden of cancer
4.1.2. Restraints
4.1.2.1. High price associated with genomics devices
4.1.3. Opportunity
4.1.3.1. The expansion of personalized medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.2. Instruments*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Consumables
9.4. Services
10. By Technology
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.1.2. Market Attractiveness Index, By Technology
10.2. Genome Sequencing*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. PCR
10.4. Microarray
10.5. Nucleic Acid Extraction and Purification
10.6. Others
11. By Application
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Diagnostics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Personalized Medicine
11.4. Drug Discovery & Development
11.5. Research
12. By End User
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User
12.2. Hospitals*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Research Institutes
12.4. Academic Institutes
12.5. Others
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. Company Profiles
15.1. Roche Diagnostics*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. AstraZeneca PLC
15.3. Illumina, Inc
15.4. Affymetrix
15.5. Agilent Technologies
15.6. Cancer Genetics Inc.
15.7. Beckman Coulter Inc.
15.8. Bio-Rad Labs
15.9. Danaher Corporation
15.10. Sigma Aldrich Corporation (Merck KGaA)
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Roche Diagnostics, 4.	Key Developments, AstraZeneca PLC, Illumina, Inc, Affymetrix, Agilent Technologies, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, Sigma Aldrich Corporation (Merck KGaA)

표 목록 (Tables)

List of Tables Table 1 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 8 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 10 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 11 Global Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 12 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)

Table 13 Global Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 14 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 15 Global Genomics in Cancer Care Market Value, By Region, 2022-2033 (US$ Billion)

Table 16 North America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 17 North America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 18 North America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 19 North America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 20 North America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Europe Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 22 Europe Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 23 Europe Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 24 Europe Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 25 Europe Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)

Table 26 Asia-Pacific Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 27 Asia-Pacific Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 28 Asia-Pacific Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 29 Asia-Pacific Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 30 Asia-Pacific Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)

Table 31 South America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 32 South America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 33 South America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 34 South America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 35 South America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)

Table 36 Middle East and Africa Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 37 Middle East and Africa Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)

Table 38 Middle East and Africa Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)

Table 39 Middle East and Africa Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)

Table 40 Middle East and Africa Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)

Table 41 Illumina: Overview

Table 42 Illumina: Product Portfolio

Table 43 Illumina: Key Developments

Table 44 Thermo Fisher Scientific: Overview

Table 45 Thermo Fisher Scientific: Product Portfolio

Table 46 Thermo Fisher Scientific: Key Developments

Table 47 BGI Genomics: Overview

Table 48 BGI Genomics: Product Portfolio

Table 49 BGI Genomics: Key Developments

Table 50 QIAGEN: Overview

Table 51 QIAGEN: Product Portfolio

Table 52 QIAGEN: Key Developments

Table 53 Roche Diagnostics: Overview

Table 54 Roche Diagnostics: Product Portfolio

Table 55 Roche Diagnostics: Key Developments

Table 56 Guardant Health: Overview

Table 57 Guardant Health: Product Portfolio

Table 58 Guardant Health: Key Developments

Table 59 Natera: Overview

Table 60 Natera: Product Portfolio

Table 61 Natera: Key Developments

Table 62 Myriad Genetics: Overview

Table 63 Myriad Genetics: Product Portfolio

Table 64 Myriad Genetics: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 4 Global Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 5 Global Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 6 Global Genomics in Cancer Care Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Genomics in Cancer Care Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 8 Instruments Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 9 Consumables Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 10 Global Genomics in Cancer Care Market Y-o-Y Growth, By Technology, 2023-2033 (%)

Figure 11 Next Generation Sequencing Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 12 PCR Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 13 Microarrays Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 14 Nuclei Acid Extraction and Purification Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 15 Others Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 16 Global Genomics in Cancer Care Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 17 Diagnostics Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 18 Personalized Medicine Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 19 Drug Discovery & Development Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Genomics in Cancer Care Market Y-o-Y Growth, By End User, 2023-2033 (%)

Figure 21 Hospitals & Oncology Clinics End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 22 Diagnostic Labs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 23 Academic & Research Centers End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 24 Pharma & CROs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 25 Global Genomics in Cancer Care Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 26 North America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 27 North America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 28 North America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 29 North America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 30 North America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 31 North America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)

Figure 32 Europe Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 33 Europe Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 34 Europe Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 35 Europe Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 36 Europe Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 37 Europe Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)

Figure 38 Asia-Pacific Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 39 Asia-Pacific Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 40 Asia-Pacific Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 41 Asia-Pacific Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 42 Asia-Pacific Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 43 Asia-Pacific Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)

Figure 44 South America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 45 South America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 46 South America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 47 South America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 48 South America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 49 South America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)

Figure 50 Middle East and Africa Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)

Figure 51 Middle East and Africa Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)

Figure 52 Middle East and Africa Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)

Figure 53 Middle East and Africa Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)

Figure 54 Middle East and Africa Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)

Figure 55 Illumina: Financials

Figure 56 Thermo Fisher Scientific: Financials

Figure 57 BGI Genomics: Financials

Figure 58 QIAGEN: Financials

Figure 59 Roche Diagnostics: Financials

Figure 60 Guardant Health: Financials

Figure 61 Natera: Financials

Figure 62 Myriad Genetics: Financials

글로벌 암 치료 분야 유전체학 시장 – 2023-2030

Global Genomics in Cancer Care Market - 2023-2030